Affinage

RARS1

Arginine--tRNA ligase, cytoplasmic · UniProt P54136

Round 2 corrected
Length
660 aa
Mass
75.4 kDa
Annotated
2026-04-28
73 papers in source corpus 10 papers cited in narrative 10 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RARS1 encodes the cytoplasmic arginyl-tRNA synthetase that charges tRNAArg with arginine for protein translation and assembles as a stable subunit of the multisynthetase complex (MSC), where its integration is essential for proper forebrain neurodevelopment and translational fidelity (PMID:28905880, PMID:33515434). Biallelic loss-of-function mutations cause hypomyelinating leukodystrophy (HLD9) through at least three distinct mechanisms: loss of aminoacylation catalytic activity (R512Q, ΔC frameshifts), reduced mRNA translation via an inhibitory upstream ORF (c.5A>G), or mislocalization of the mutant protein to lysosomes with impaired ribosomal S6 phosphorylation and failed oligodendrocyte differentiation (S456L) (PMID:33515434, PMID:31737794, PMID:24777941). Beyond its canonical role, RARS1 sequesters AIMP1 within the MSC to regulate its cytokine secretion and stabilizes ENO1 by blocking its ubiquitination, thereby suppressing ferroptosis through the PI3K/AKT/GSK3β axis (PMID:17443684, PMID:41451236). The RARS1 disease spectrum extends beyond hypomyelination to include developmental and epileptic encephalopathy with cortical malformations (PMID:37186453).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2007 Medium

    Establishing that RARS1 has a non-canonical function in cytokine regulation: RARS1 association with AIMP1 within the multisynthetase complex prevents AIMP1 secretion, revealing that the MSC serves as a sequestration platform controlling cytokine release.

    Evidence RARS1 overexpression in HeLa and MCF7 cells with AIMP1 secretion and cleavage assays

    PMID:17443684

    Open questions at the time
    • No structural mapping of the RARS1-AIMP1 interface within the MSC
    • Physiological relevance of AIMP1 retention not tested in vivo
    • Mechanism linking proteasomal cleavage to EMAP II maturation incompletely defined
  2. 2014 Medium

    Identification of RARS1 as a disease gene: compound heterozygous RARS1 mutations were shown to cause hypomyelinating leukodystrophy (HLD9), establishing the first genetic link between cytoplasmic arginyl-tRNA synthetase and CNS myelination.

    Evidence MRI pattern recognition and whole exome sequencing in four patients with hypomyelination

    PMID:24777941

    Open questions at the time
    • No in vitro enzymatic or protein-level validation of the identified variants
    • Mechanism by which reduced ArgRS activity impairs myelination not addressed
    • No animal model confirming causality
  3. 2017 Medium

    Demonstrating that patient mutations drastically reduce both RARS1 and MSC protein levels and impair arginine-dependent protein synthesis, linking the genetic findings to a biochemical deficiency in aminoacylation capacity.

    Evidence Western blot, Blue native-PAGE, and proliferation assays under arginine-limiting conditions in patient fibroblasts

    PMID:28905880

    Open questions at the time
    • Direct aminoacylation kinetics not measured
    • Contribution of reduced MSC integrity versus reduced RARS1 catalytic activity not disentangled
    • Oligodendrocyte-specific consequences not tested
  4. 2019 Medium

    Revealing a localization-dependent pathogenic mechanism: the HLD9-associated S456L mutation mislocalizes RARS1 to lysosomes, suppresses ribosomal S6 phosphorylation, and blocks oligodendrocyte differentiation, establishing that subcellular mislocalization rather than simple catalytic loss can drive disease.

    Evidence Confocal immunofluorescence with organelle markers and S6 phosphorylation/differentiation assays in FBD-102b oligodendroglial cells

    PMID:31737794

    Open questions at the time
    • Mechanism of lysosomal targeting of S456L mutant not determined
    • Link between lysosomal RARS1 accumulation and S6 phosphorylation suppression not mechanistically resolved
    • Single cell line used for differentiation assay
  5. 2021 High

    Dissecting distinct pathogenic mechanisms of RARS1 mutations: R512Q and ΔC frameshifts directly impair aminoacylation activity, whereas the common c.5A>G variant reduces RARS1 mRNA translation via an upstream open reading frame without affecting enzyme function, establishing genotype-mechanism heterogeneity in HLD9.

    Evidence In vitro aminoacylation assays, structural analysis, and uORF-mediated translational regulation assays

    PMID:33515434

    Open questions at the time
    • Relative contribution of each mechanism to clinical severity not quantified
    • uORF regulation not validated in oligodendrocyte-lineage cells
    • No rescue experiment demonstrating that restoring RARS1 levels corrects the translational defect
  6. 2023 Medium

    Expanding the RARS1 disease spectrum beyond hypomyelination: novel biallelic variants reduce ArgRS protein stability and cause developmental and epileptic encephalopathy with cortical malformations, demonstrating that RARS1 deficiency affects brain development more broadly than myelin alone.

    Evidence In vitro protein expression and stability assays combined with clinical characterization of 29 patients

    PMID:37186453

    Open questions at the time
    • No direct aminoacylation assays for the novel variants
    • Cortical developmental mechanism not investigated
    • Genotype-phenotype correlations across the full spectrum remain incomplete
  7. 2025 Medium

    Uncovering a non-canonical anti-ferroptotic role: RARS1 physically interacts with ENO1 and blocks its ubiquitination-dependent degradation, thereby sustaining PI3K/AKT/GSK3β signaling and suppressing ferroptosis in hepatocellular carcinoma.

    Evidence Co-immunoprecipitation, ubiquitination assays, RARS1 knockdown/overexpression, ferroptosis readouts in hepatocellular carcinoma cells

    PMID:41451236

    Open questions at the time
    • Single-lab finding; ENO1 stabilization not validated in non-cancer cells
    • Domain on RARS1 mediating ENO1 interaction not mapped
    • Relationship between aminoacylation activity and ENO1 stabilization function unclear
  8. 2025 Medium

    Demonstrating in vivo that RARS1 integration into the MSC is required for forebrain development: conditional exclusion from the MSC in mouse forebrain causes severe microcephaly, behavioral deficits, and dysregulated neurodevelopmental and ribosomal gene programs, with altered RARS1 subcellular localization.

    Evidence Conditional mouse knockout model with brain morphometry, behavioral assays, transcriptomics, and immunofluorescence (preprint)

    PMID:bio_10.1101_2025.09.08.674979

    Open questions at the time
    • Preprint; not yet peer-reviewed
    • Whether phenotype reflects loss of catalytic activity, loss of MSC scaffolding, or both is unresolved
    • Oligodendrocyte-specific versus neuron-specific contributions not disentangled

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of RARS1 integration into the MSC and how that integration coordinates canonical aminoacylation with non-canonical signaling functions, the cell-type-specific mechanisms by which RARS1 deficiency differentially affects oligodendrocytes versus cortical neurons, and whether the ENO1-stabilizing anti-ferroptotic function operates in physiological non-cancer contexts.
  • No high-resolution structure of RARS1 within the full MSC
  • Cell-type-specific conditional models for oligodendrocytes versus neurons not yet compared
  • ENO1 interaction not tested outside hepatocellular carcinoma

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016874 ligase activity 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005829 cytosol 2 GO:0005764 lysosome 1
Pathway
R-HSA-1643685 Disease 3 R-HSA-392499 Metabolism of proteins 2
Partners
AIMP1AIMP2ENO1
Complex memberships
multisynthetase complex (MSC)

Evidence

Reading pass · 10 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 RARS1 overexpression impairs AIMP1 (EMAP II precursor) secretion in HeLa and MCF7 cells, suggesting that RARS1 association with AIMP1 within the multisynthetase complex prevents its secretion; additionally, proteasome inhibition blocks cleavage of AIMP1 to generate the mature cytokine EMAP II, implicating the proteasome in EMAP II maturation. RARS1 overexpression in cell lines (HeLa, MCF7) with measurement of AIMP1 secretion; proteasome inhibitor treatment with AIMP1 cleavage assays Journal of cellular physiology Medium 17443684
2014 Compound heterozygous mutations in RARS1 (encoding cytoplasmic arginyl-tRNA synthetase) cause hypomyelinating leukodystrophy; RARS1 is identified as a subunit of the multisynthetase complex, which is implicated as a key player in myelination. MRI pattern recognition combined with whole exome sequencing in four patients with hypomyelination; genetic identification of RARS1 compound heterozygous mutations Annals of neurology Medium 24777941
2017 RARS1 mutations (including homozygous c.5A>G p.Asp2Gly and compound heterozygous c.1367C>T p.Ser456Leu / c.1846_1847delTA p.Tyr616Leufs*6) reduce RARS1 protein levels by ~80% and reduce multisynthetase complex levels by ~90% as measured by western blotting and Blue native-PAGE in patient fibroblasts; patient fibroblasts show significantly reduced proliferation under arginine-limiting conditions, demonstrating impaired protein synthesis capacity. Western blotting, Blue native-PAGE of patient fibroblast extracts; fibroblast proliferation assay under arginine-limited conditions at 30°C and 40°C European journal of human genetics Medium 28905880
2017 The RARS1-MAD1L1 fusion protein (arising from chromosomal translocation) interacts with AIMP2, leading to activation of the FUBP1/c-Myc pathway; this interaction promotes cancer stem cell-like properties and chemo/radioresistance in nasopharyngeal carcinoma; silencing FUBP1 or inhibiting c-Myc abrogates fusion-induced CSC characteristics. Co-immunoprecipitation, chromatin immunoprecipitation, colony/sphere formation assays, MTT assay, in vivo chemoresistance assay, RNA-seq fusion detection, PCR, FISH Clinical cancer research Medium 29133573
2019 The HLD9-associated missense mutation S456L in RARS1 causes the protein to accumulate as aggregates in lysosomes rather than distributing throughout the cytoplasm as wild-type RARS1 does; S456L mutant expression decreases lysosome-related ribosomal S6 protein phosphorylation (required for myelination) and abolishes myelin web-like structure formation during oligodendroglial differentiation in FBD-102b cells. Immunofluorescence/confocal microscopy for subcellular localization (comparing ER, Golgi, lysosome markers); western blot for S6 phosphorylation; oligodendroglial differentiation assay in FBD-102b cells Biochemistry and biophysics reports Medium 31737794
2021 RARS1 mutations linked to Pelizaeus-Merzbacher-like disease (PMLD) act through distinct pathogenic mechanisms: the R512Q substitution and ΔC frameshift mutations (p.Y616Lfs*6) impair hArgRS protein structure and aminoacylation activity; in contrast, the most frequent mutation c.5A>G (p.D2G) does not impair hArgRS enzymatic activity but instead reduces translation of hArgRS mRNA, with an upstream open reading frame contributing to suppressed translation of the main downstream ORF. In vitro aminoacylation activity assays; structural analysis; mRNA translation assays; upstream ORF identification and functional characterization Science China. Life sciences High 33515434
2023 Biallelic RARS1 variants (c.1535G>A p.Arg512Gln, c.1382G>A p.Arg461His, and homozygous c.5A>T p.Asp2Val) reduce ArgRS protein expression and stability in vitro; the c.5A>T variant causes severe developmental and epileptic encephalopathy phenotype, extending the RARS1 disease spectrum beyond hypomyelination to cortical developmental malformations. In vitro functional validation of variants; protein expression and stability assays; clinical characterization and literature review of 29 patients Epilepsia open Medium 37186453
2016 Ischemic injury induces upregulation of Rars transcriptional activity and ArgRS protein overexpression in primary cultured neurons, peaking at 6 hours post-reoxygenation; ischemic preconditioning (IPC) suppresses this Rars upregulation and reduces ArgRS levels, suggesting that IPC-mediated neuroprotection involves downregulation of Rars/ArgRS. Oxygen-glucose deprivation model in primary cultured neurons; RT-PCR for Rars transcriptional activity; western blot for ArgRS protein levels at multiple time points post-reoxygenation; IPC vs. PI group comparison Journal of Huazhong University of Science and Technology. Medical sciences Low 27465332
2025 RARS1 mechanistically inhibits ferroptosis in hepatocellular carcinoma by preventing ENO1 ubiquitination and proteasomal degradation; RARS1 knockdown reduces ENO1 protein levels, promotes ferroptosis, and inhibits the PI3K/AKT/GSK3β pathway; RARS1 overexpression stabilizes ENO1 by blocking its ubiquitination. RARS1 knockdown and overexpression; co-immunoprecipitation and ubiquitination assays for ENO1; PI3K/AKT/GSK3β pathway analysis; ferroptosis assays; in vitro drug sensitivity analysis with AH.6809 Frontiers in immunology Medium 41451236
2025 RARS1 integration into the multisynthetase complex is required for proper mammalian forebrain development; a mouse model excluding RARS1 from the multisynthetase complex in the forebrain shows drastically reduced forebrain size, behavioral deficits, dysregulation of neurodevelopmental and ribosomal genes, and perturbed subcellular localization of RARS1 and its colocalization with other translational machinery components. Conditional mouse knockout model (RARS1 excluded from multisynthetase complex in forebrain); brain morphometry; behavioral assays; transcriptomic analysis; immunofluorescence for RARS1 localization and colocalization with translational machinery bioRxivpreprint Medium bio_10.1101_2025.09.08.674979

Source papers

Stage 0 corpus · 73 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2011 Systematic and quantitative assessment of the ubiquitin-modified proteome. Molecular cell 1334 21906983
2015 The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 1118 26186194
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2020 A reference map of the human binary protein interactome. Nature 849 32296183
2018 VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell discovery 829 29507755
1994 Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development (Cambridge, England) 803 7607068
2011 A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Molecular & cellular proteomics : MCP 749 21890473
2007 Large-scale mapping of human protein-protein interactions by mass spectrometry. Molecular systems biology 733 17353931
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2012 A census of human soluble protein complexes. Cell 689 22939629
2015 Gene essentiality and synthetic lethality in haploid human cells. Science (New York, N.Y.) 657 26472760
1994 Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. Development (Cambridge, England) 657 7607067
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2008 Large-scale proteomics and phosphoproteomics of urinary exosomes. Journal of the American Society of Nephrology : JASN 607 19056867
2011 Global landscape of HIV-human protein complexes. Nature 593 22190034
1994 Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. Gene 492 8125298
2003 Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nature biotechnology 485 12665801
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
2015 Panorama of ancient metazoan macromolecular complexes. Nature 407 26344197
1996 Normalization and subtraction: two approaches to facilitate gene discovery. Genome research 401 8889548
2011 Global identification of modular cullin-RING ligase substrates. Cell 354 21963094
2010 Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 318 21145461
1993 RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. The EMBO journal 303 8389696
2012 A high-throughput approach for measuring temporal changes in the interactome. Nature methods 273 22863883
2010 Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. Molecular & cellular proteomics : MCP 262 21139048
2017 A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. Molecular cell 248 28431233
2012 Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nature cell biology 243 23000965
2015 La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1). The Journal of biological chemistry 213 25940091
2015 ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 209 26618866
2006 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 141 16741247
2009 Developmental expression of retinoic acid receptors (RARs). Nuclear receptor signaling 109 19471585
1990 Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors (RAR's). Biochemical and biophysical research communications 97 2154975
2014 Mutations in RARS cause hypomyelination. Annals of neurology 94 24777941
2012 Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ). The Journal of biological chemistry 91 23105114
2001 F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histology and histopathology 72 11510982
2016 Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. American journal of hematology 62 26874914
1997 Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells. The Journal of biological chemistry 62 9228081
1994 c-erbA alpha/T3R and RARs control commitment of hematopoietic self-renewing progenitor cells to apoptosis or differentiation and are antagonized by the v-erbA oncogene. Oncogene 61 7906409
2017 The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 50 29133573
1996 Inhibition of rabbit collagenase (matrix metalloproteinase-1; MMP-1) transcription by retinoid receptors: evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. Journal of cellular physiology 44 8908199
2001 Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells. British journal of cancer 40 11487280
2003 Retinoid receptors and vitamin A deficiency: differential patterns of transcription during early avian development and the rapid induction of RARs by retinoic acid. Developmental biology 38 12921748
2017 Mutations in RARS cause a hypomyelination disorder akin to Pelizaeus-Merzbacher disease. European journal of human genetics : EJHG 34 28905880
2015 Refractory anemia with ring sideroblasts and RARS with thrombocytosis. American journal of hematology 32 25899435
2012 Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leukemia research 31 22921191
2022 Retinoic acid, RARs and early development. Journal of molecular endocrinology 30 35593389
2005 Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs. Nutrition and cancer 19 16091010
2008 The role of JAK2 mutations in RARS and other MDS. Hematology. American Society of Hematology. Education Program 18 19074058
1994 Expression of the retinoic Acid nuclear receptors (rars) and retinoid x-receptor (rxr) genes in estrogen-receptor positive and negative breast-cancer. International journal of oncology 16 21566993
2003 Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT). Annals of hematology 15 14615911
2014 RARs and microRNAs. Sub-cellular biochemistry 14 24962885
2019 Hypomyelinating Leukodystrophy with Spinal Cord Involvement Caused by a Novel Variant in RARS: Report of Two Unrelated Patients. Neuropediatrics 13 30791064
2007 Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. Journal of cellular physiology 13 17443684
2016 Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). Leukemia & lymphoma 12 27771989
2011 Proliferation of cells and expression of RARs, RXRs and HPV viral E6 and E7 proteins in cervical cancer cell lines after treatment with ATRA. Annals of agricultural and environmental medicine : AAEM 10 21736279
2021 Distinct pathogenic mechanisms of various RARS1 mutations in Pelizaeus-Merzbacher-like disease. Science China. Life sciences 9 33515434
2023 Circular RNA, circular RARS, promotes aerobic glycolysis of non-small-cell lung cancer by binding with LDHA. Thoracic cancer 8 36628612
2019 Hypomyelinating leukodystrophy-associated mutation of RARS leads it to the lysosome, inhibiting oligodendroglial morphological differentiation. Biochemistry and biophysics reports 8 31737794
2012 The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation. Journal of leukocyte biology 8 23136256
2010 Chromosomes in a hybrid zone of Israeli mole rars (Spalax, Rodentia). Genetika 5 21250542
1996 Dexamethasone decreases the expression of retinoic acid receptors (RARs) in rat liver. The Journal of steroid biochemistry and molecular biology 5 8645624
2012 RARS with fibrosis and del(20q) transformed into ALL. Medical oncology (Northwood, London, England) 4 22760793
2023 RARS1-related developmental and epileptic encephalopathy. Epilepsia open 3 37186453
2003 Nucleolar abnormalities--a defect of the nucleolar preribosome assembly--in ringed sideroblasts in refractory anaemia with ringed sideroblasts (RARS) of myelodysplastic syndrome (MDS). An electron microscopic study. Sbornik lekarsky 3 14577129
2016 Ischemic preconditioning inhibits over-expression of arginyl-tRNA synthetase gene Rars in ischemia-injured neurons. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2 27465332
2004 Accumulation of homoplasmic mtDNA point mutations in erythroblasts isolated from the bone marrow of patients with refractory anemia with ring sideroblasts (RARS). Mitochondrion 2 16120395
1993 Progression of refractory anaemia with ringed sideroblasts (RARS) to B-acute lymphoblastic leukaemia. Haematologia 1 8157211
2025 RARS1 inhibits ENO1 ubiquitination and degradation to protect against ferroptosis in hepatocellular carcinoma. Frontiers in immunology 0 41451236
1996 Murine endodermal F9E cells, derived from the teratocarcinoma line F9, contain high basal levels of retinoic acid receptors (RARs and RXRs) but are not sensitive to the actions of retinoic acid. Differentiation; research in biological diversity 0 8765051